Home › Cytomegalovirus Infections › NCT06407232

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* undergone kidney or simultaneous kidney/pancreas transplant
* high-risk CMV serostatus (D+/R-) at time of transplant
* develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
* demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
* able to provide informed consent to participate

Exclusion Criteria:

* contraindication to letermovir or its excipients
* develop ganciclovir-resistant CMV infection
* currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
* unable or unwilling, in the opinion of the Investigator, to comply with the protocol
* pregnant or breastfeeding

About the study

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

What is being tested

• Letermovir (drug)

Sponsor: University of Wisconsin, Madison · Participants: 90 · Started: Aug 8, 2024

Contact the study team

• Sandesh Parajuli, MBBS · Phone: (608) 262-2122

Official record on ClinicalTrials.gov — NCT06407232

Locations in the U.S.

Conditions

• Cytomegalovirus Infections

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.